成年软组织肉瘤免疫疗法耐药性的潜在机制
Zaina S Kret1, Ryan J Sweder2, Raphael Pollock3
1The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Targeted oncology
|April 27, 2025
概括
软组织肉瘤是一种罕见的癌症,存活率很低. 目前的免疫疗法由于瘤的"寒冷"免疫环境而扎,缺乏有效治疗的预测生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 软组织瘤 (STS) 是一种罕见的间细胞恶性瘤,占美国成人癌症的<1%.
- 转移性STS患者的选择有限,预后不佳,平均总生存期为18个月.
- 免疫疗法在STS中具有挑战性,原因是"冷"的瘤免疫微环境和缺乏特定的生物标志物.
研究的目的:
- 审查软组织肉瘤中免疫疗法耐药性的机制.
- 确定挑战,并探索新兴的提高STS免疫疗法疗效的策略.
- 讨论瘤微环境和免疫相关基因在STS免疫治疗中的作用.
主要方法:
- 对软组织肉瘤免疫学和免疫治疗研究的文献综述.
- 分析导致STS患者免疫逃避的因素.
- 检查当前和新兴的治疗策略.
主要成果:
- STS瘤通常表现出"冷"的免疫特征,阻碍T细胞透和反应.
- 没有一致的生物标志物可靠地预测各种STS亚型的免疫治疗反应.
- 天生的/适应性免疫和瘤微环境的相互作用显著影响了耐药性.
结论:
- 在STS中克服免疫疗法耐药性需要了解复杂的免疫相互作用.
- 目前正在研究将"冷"瘤转化为"热"瘤的策略.
- 个性化治疗方法有望改善异质性STS的结果.
更多相关视频
08:06Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
19.3K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.1K
相关概念视频
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:27Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
02:17The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
02:40Cancer Stem Cells and Tumor Maintenance
4.6K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.6K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K